Bosnia and Herzegovina vs Denmark: Tuberculosis treatment success rate
Bosnia and Herzegovina
37.0%
in 2023
Denmark
30.0%
in 2023
Bosnia and Herzegovina rank
197th
Denmark rank
200th
Tuberculosis treatment success rate over time
- Bosnia and Herzegovina
- Denmark
How they compare
Bosnia and Herzegovina currently reports 37.0% against 30.0% in Denmark, a difference of 7.0%.
That makes Bosnia and Herzegovina's figure about 1.2 times Denmark's.
The two have swapped places 2 times across 24 shared years of data; in 2000 it was Bosnia and Herzegovina ahead.
Bosnia and Herzegovina ranks 197th and Denmark ranks 200th of 206 countries.
Bosnia and Herzegovina has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | Denmark | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 95.8% | 80.8% | 15.0% | Bosnia and Herzegovina |
| 2010s | 63.9% | 49.9% | 14.0% | Bosnia and Herzegovina |
| 2020s | 45.2% | 25.5% | 19.8% | Bosnia and Herzegovina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis treatment success rate, Bosnia and Herzegovina or Denmark?
- Bosnia and Herzegovina, at 37.0% against 30.0% in Denmark as of 2023.
- What is the difference in tuberculosis treatment success rate between Bosnia and Herzegovina and Denmark?
- 7.0%, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Denmark?
- 24 years are reported by both, from 2000 to 2023.
- How do Bosnia and Herzegovina and Denmark rank globally for tuberculosis treatment success rate?
- Bosnia and Herzegovina ranks 197th and Denmark ranks 200th of 206 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Tuberculosis treatment success rate. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Treatment success rate among new and relapse cases.